Effects of U83836E on nerve functions, hyperalgesia and oxidative stress in experimental diabetic neuropathy by Sayyed, Sufyan Ali
06) 777–783
www.elsevier.com/locate/lifescieLife Sciences 79 (20Effects of U83836E on nerve functions, hyperalgesia and oxidative stress
in experimental diabetic neuropathy
Sufyan G. Sayyed, Ashutosh Kumar, Shyam S. Sharma ⁎
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Sec-67,
S.A.S. Nagar (Mohali), Punjab-160062, India
Received 5 August 2005; accepted 22 February 2006Abstract
Oxidative stress has been implicated to play an important role in the pathogenesis of diabetic neuropathy, which is the most common
complication of diabetes mellitus affecting more than 50% of diabetic patients. In the present study, we have investigated the effect of U83836E
[(−)-2-((4-(2,6-Di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl)methyl)-3,4-dihydro-2,3,7,8-tetramethyl-2H-1-benzopyran-6-ol, 2HCl], a potent
free radical scavenger in streptozotocin (STZ)-induced diabetic neuropathy in rats. STZ-induced diabetic rats showed significant deficit in motor
nerve conduction velocity (MNCV), nerve blood flow (NBF) and thermal hyperalgesia after 8weeks of diabetes induction, indicating development
of diabetic neuropathy. Antioxidant enzyme (superoxide dismutase and catalase) levels were reduced and malondialdehyde (MDA) levels were
significantly increased in diabetic rats as compared to the age-matched control rats, this indicates the involvement of oxidative stress in diabetic
neuropathy. The 2-week treatment with U83836E (3 and 9mg/kg, i.p.) started 6weeks after diabetes induction significantly ameliorated the
alterations in MNCV, NBF, hyperalgesia, MDA levels and antioxidant enzymes in diabetic rats. Results of the present study suggest the potential
of U83836E in treatment of diabetic neuropathy.
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Diabetes mellitus is one of the serious problems in
developing as well as developed countries. The number of
people affected with diabetes worldwide is projected to be 366
million by year 2030 (Wild et al., 2004). Uncontrolled chronic
hyperglycemia in diabetic patients leads to several complica-
tions including retinopathy, nephropathy, autonomic dysfunc-
tions and neuropathy. Diabetic neuropathy is the most common
complication affecting more than 50% of diabetic patients.
Diabetes-induced deficits in motor and sensory nerve conduc-
tion velocities and other manifestations of peripheral diabetic
neuropathy (PDN) have been well correlated with chronic
hyperglycemia. Hyperglycemia has been reported to result in
increased polyol pathway activity, oxidative stress, advanced
glycation end product formation (AGE), nerve hypoxia/
ischemia, increased activation of protein kinase C and impaired⁎ Corresponding author. Tel.: +91 172 2214683 to 87; fax: +91 172 2214692.
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doi:10.1016/j.lfs.2006.02.033nerve growth factor support (Sima and Sugimoto, 1999; van
Dam, 2002; Feldman, 2003; Obrosova, 2003; Vincent et al.,
2004). All these pathways contribute to the development of
diabetic neuropathy.
Oxidative stress resulting from enhanced free radical
formation and/or a defect in antioxidant defenses has been
implicated in the pathogenesis of experimental diabetic
neuropathy. Reactive oxygen species (superoxide radical,
hydrogen peroxide and hydroxyl radical) and reactive nitrogen
species (peroxynitrite) contribute to pathophysiological changes
in diabetic neuropathy (Vincent et al., 2004). Antioxidant
enzyme defense system (Superoxide dismutase, catalase and
glutathione peroxidase) is also attenuated in peripheral nerves
of diabetic animals indicating the vital role of oxidative stress in
diabetic neuropathy (Low et al., 1997). Several mechanisms
including auto oxidative glycosylation, formation of AGE and
increased polyol pathway activity contribute to increased
oxidative stress (Van Dam, 2002; Vincent et al., 2004).
Oxidative stress also activates down stream pathways such as
poly(ADP-ribose) polymerase (PARP) and mitogen-activated
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2004). Oxidative stress causes vascular impairment leading to
endoneurial hypoxia resulting in impaired neural function
(Wang et al., 2002; Yorek et al., 2004), reduced nerve
conduction velocity and loss of neurotrophic support. Long-
term oxidative stress can also mediate apoptosis of neurons and
Schwann cells leading to nerve damage (Sekido et al., 2004).
Above-mentioned studies suggest that oxidative stress may be
one of the major pathway in the development of diabetic
neuropathy and that an antioxidant can prevent or reverse
hyperglycemia-induced nerve dysfunctions.
Several antioxidants such as α-lipoic acid, taurine, acetyl-L-
carnitine, M40403 and β-carotene have demonstrated to
ameliorate nerve function deficit in experimental diabetic
neuropathy (Cameron and Cotter, 1999; Coppey et al., 2001a,
b; Heller et al., 2004; Karasu et al., 1995; Love et al., 1996;
Nickander et al., 1996; Rosen et al., 1995). These reports
suggest that reducing oxidative stress may inhibit the
development of diabetic neuropathy. Therefore, in the present
study, we have investigated the effect of U83836E, a potent free
radical scavenger on nerve functions, nociception and oxidative
stress in streptozotocin (STZ)-induced diabetic neuropathy
model in rats.
Materials and methods
Chemicals and drug solution preparation
U83836E [(−)-2-((4-(2,6-Di-1-pyrrolidinyl-4-pyrimidinyl)-
1-piperazinyl)methyl)-3,4-dihydro-2,3,7,8-tetramethyl-2H-1-
benzopyran-6-ol, 2HCl] was purchased from Calbiochem,
Germany. Atropine sulphate and STZ were procured from
Sigma, U.S.A. Thiopentone sodium was obtained from Neon,
India. Glucose oxidase–peroxidase (GOD/POD) glucose kit
was purchased from Accurex, India. All other chemicals of
analytical grade were purchased locally. STZ was dissolved in
citrate buffer (pH 4.4) and U83836E was dissolved in distilled
water.
Animals
Healthy male Sprague–Dawley rats (250–270g, 8–10weeks
old) were obtained from the Central Animal Facility (CAF),
National Institute of Pharmaceutical Education and Research
(NIPER). Animals were provided with standard diet and water
ad libitum. They were housed in plastic cages (three in each) at a
controlled temperature of 24±1°C and humidity of 55±5%,
with 12-h light and dark cycle. All animals were acclimatized
for minimum period of 1week prior to the beginning of study.
The experimental protocols were approved by the Institutional
Animal Ethics Committee of NIPER.
Induction of diabetes
A single dose of STZ (55mg/kg, i.p.) was used for induction
of type I diabetes in rats. Age-matched control rats received the
equal volume of vehicle (citrate buffer). Diabetes wasconfirmed after 48h of STZ injection by estimating plasma
glucose levels using GOD/POD kit. Rats with plasma glucose
levels of >250mg/dl were included for further studies.
Experimental design and drug treatment
We have reported earlier that diabetic neuropathy develop
within 6weeks after the induction of diabetes (Kumar et al.,
2005). In this study, development of diabetic neuropathy was
ensured before starting the treatment by measuring motor nerve
conduction velocity (MNCV) and hyperalgesia after 6weeks of
diabetes induction. Six weeks after the diabetic induction
therapeutic treatment with U83836E (3 and 9mg/kg, i.p., daily)
was given for 2weeks (7th and 8th weeks). All parameters
(MNCV, nerve blood flow (NBF), hyperalgesia, lipid peroxida-
tion and antioxidant enzyme activity level) were evaluated on
completion of treatment.
MNCV measurement
Power Lab 8sp system (ADInstruments, Australia) was used
for the measurement of MNCV. MNCV was measured in
anesthetized rats by stimulating the sciatic (proximal to sciatic
notch) and tibial (proximally to ankle) nerve using bipolar
needle (26.5-gauge) electrodes with 3V, single stimulus exactly
as described previously (Kumar et al., 2005; Saini et al., 2004).
During the study, body temperature of rats was maintained at
37°C using homeothermic blanket system (Harvard, UK).
MNCV was calculated by following formula:
MNCV ¼ ðdistance between sciatic and tibial nerve stimulation pointÞ
=ðsciatic M wave latency−tibial M wave latencyÞ:
Composite NBF measurement
Nerve blood flow was measured using laser Doppler
flowmeter (Perimed, Sweden). Animals were anaesthetized by
administering 1.5% thiopentone sodium (30mg /kg, i.p.) and
placed on stereotaxic apparatus to achieve uniform position of
laser Doppler probe. Sciatic nerve of left flank was exposed
and laser probe placed just above the nerve. Animals were
stabilized for 15min prior to 10-min continuous NBF
recording, as per previously described procedure (Kumar et
al., 2005; Saini, et al., 2004). Average values of 10-min
recording were represented as perfusion unit. During the
study, body temperature of rats was maintained at 37°C using
homeothermic blanket system (Harvard, UK) and sciatic
nerve temperature was monitored using digital thermometer
(Century, India). Laser Doppler technique is considered to be
an appropriate method for the measurement of composite
sciatic NBF (Stevens et al., 1994), even though it cannot
discriminate between endoneurial and epineurial blood flow.
Data obtained from laser Doppler flowmeter have been
reported to have a significant correlation between conven-
tional techniques such as the hydrogen clearance method
(Takeuchi and Low, 1987) and the 14C iodoantipyrine method
(Rundquist et al., 1985).
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Hyperalgesia was assessed by tail immersion test (Courteix
et al., 1993). Rat tail was immersed in cold water (10°C—for
cold immersion test) or warm water (45°C—for hot immersion
test) and the tail flick response latency (withdrawal response of
tail) was observed as the end point response.
Lipid peroxidation
Lipid peroxidation was estimated by measuring the formed
malondialdehyde (MDA) colorimetrically using method de-
scribed by Zhang et al. (2004). Sciatic nerve was isolated
bilaterally from the inguinal ligament to its trifurcation. Isolated
nerve was homogenized in 1ml of 100mM phosphate buffer
solution (PBS) having pH 7.4 using polytron homogenizer. An
aliquot (100μl) of homogenate was added to a reaction mixture
containing 50μl of 8.1% sodium dodecyl sulphate, 300μl of
20% acetic acid, 300μl of 0.8% thiobarbituric acid and 60μl
distilled water in a tightly closed caped tubes. Samples were
then incubated at 95°C for 1h, after incubation samples were
cooled to room temperature and then centrifuged at 4000×g for
10min. Supernatant was removed and absorbance was taken at
532nm; quantification was done using the standard curve
generated with authentic MDA following similar conditions.




Sciatic nerve was isolated bilaterally from the inguinal
ligament to its trifurcation. The isolated nerve was then
homogenized in 1ml of 100mM PBS pH 7.4 using polytron
homogenizer. Homogenate was then centrifuged at 4°C, 15,000
rpm for 10min. Then, supernatant was used for the measure-
ment of catalase activity by H2O2 degradation method
according to Stevens et al. (2000).
SOD activity
SOD activity was assessed using NADH oxidation method
described by Paoletti and Mocali (1990). Briefly, the following
reagents were added in reaction cuvette: 800μl of triethanola-
mine–diethanolamine buffer (pH 7.4), 40μl of 7.5mM NADH,
25μl of EDTA/MnCl2 (100:50mM) (pH 7), 100μl of
homogenate (sample) or phosphate buffer (blank). After
thorough mixing, the reaction was initiated by adding 100μlTable 1
Effect of U83836E on body weight and plasma glucose levels
Normal control Diabetic control
Body weight (g) 393.33±4.45 253.83±19.19⁎⁎⁎
Plasma glucose (mg/dl) 106.96±3.15 581.51±17.48⁎⁎⁎
Values are represented as mean±S.E.M.
⁎⁎⁎ p<0.001 vs. normal control.of 10mMmercaptoethanol and reaction was followed at 340nm
using Perkin Elmer spectrophotometer. The rate of nucleotide
oxidation (in blank) and inhibition of the same by homogenate
was calculated.
Statistical analysis of the results
All the results are expressed as mean±standard error of mean
(S.E.M.). Significance of difference between the two groups
was evaluated using Student's t-test. For multiple comparisons,
one-way analysis of variance (ANOVA) was used. When
ANOVA showed significant difference, post hoc analysis was
performed with Tukey's test. P<0.05 was considered statisti-
cally significant. Statistical analysis was carried out using
Jandel Sigma Stat Version 2, software.
Results
Plasma glucose levels and body weight
STZ-induced diabetic rats showed approximately five-fold
increase in the blood glucose levels after STZ administration,
which was consistent throughout the study period. Diabetic
rats showed significant decrease in body weight as compared
to age-matched control rats. U83836E treatment did not
produce any change in body weight and plasma glucose
levels (Table 1).
Motor nerve conduction velocity
A significant decrease (12% and 14%) in MNCV was
observed after sixth and eighth weeks of diabetes
induction. MNCV in diabetic rats was 44.22±1.55m/s
(sixth week) and 42.76±1.38m/s (eighth week) as compared
to their age-matched control group (50.39±2.17m/s and
49.90±1.94m/s, respectively). Two-week U83836E (3 and
6mg/kg, i.p.) treatment produced significant reversal (78%
and 100%, respectively) of MNCV deficits in diabetic rats
(Fig. 1).
Composite nerve blood flow
Eight-week diabetic rats showed 64% reduction in NBF; this
deficit was reversed up to 13% upon treatment with U83836E
3mg/kg, which was not statistically significant, but treatment
with U83836E 9mg/kg significantly (p<0.01) reversed the
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Fig. 3. Effect of 2-week treatment with U83836E on hyperalgesia (A: cold
immersion test and B: hot immersion test). ⁎p<0.05 vs. age-matched control
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Fig. 1. Effect of 2-week treatment with U83836E on motor nerve conduction
velocity in diabetic rats. ⁎p<0.05 vs. age-matched control rats, @p<0.05 vs.
diabetic rats without treatment, ap<0.05 vs. their respective pretreatment group.
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A significant decrease in tail flick latency was observed after
sixth and eighth weeks of diabetes induction in cold and hot
immersion test (Fig. 3A and B). This deficit in tail flick response
latency was significantly (p<0.05) reversed on 2-week
treatment with U83836E 3 and 9mg/kg (Fig. 3A and B).
Lipid peroxidation
MDA level in eighth week diabetic rats was significantly
(p<0.05) increased as compared to the age-matched control rats
(15.06±0.70 vs. 12.86±0.56μM/mg of protein). Two-week
treatment with U83836E inhibited this increase in MDA levels
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Diabetic + U 83836E 9 mg/kg
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Fig. 2. Effect of 2-week treatment with U83836E on composite nerve blood
flow. Composite nerve blood flow was measured in eighth week diabetic rats
with or without treatment. ⁎⁎⁎p<0.001 vs. age-matched control rats, @@p<0.01
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Fig. 4. Effect of 2-week treatment with U83836E on MDA levels. MDA levels
were measured in eighth week diabetic rats with or without treatment. ⁎p<0.05
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Fig. 5. Effect of 2-week treatment with U83836E on catalase activity. Catalase
activity was measured in eighth week diabetic rats with or without treatment.
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Fig. 6. Effect of 2-week treatment with U83836E on SOD activity. SOD activity
was measured in eighth week diabetic rats with or without treatment. ⁎⁎p<0.01
vs. age-matched control rats, @p<0.05 vs. diabetic rats without treatment.
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In the eighth week diabetic rats, catalase activity was
significantly decreased (0.063±0.01U/mg of protein) as
compared to the age-matched control rats (0.12±0.01U/mg of
protein). Dose dependent improvement was observed up on 2-
week treatment with U83836E at 3 and 9mg/kg (Fig. 5).
SOD activity
In the eighth week diabetic rats, SOD activity was
significantly decreased (0.62±0.19U/mg of protein) as
compared to the age-matched control rats (1.72±0.18U/mg
of protein). Two-week treatment with U83836E 3mg/kg and
9mg/kg significantly (p<0.05) inhibited the decrease in SOD
activity in treated diabetic rats as compared to vehicle-treated
rats (Fig. 6).
Discussion
In our study, development of diabetic neuropathy in STZ-
induced diabetic rats was evident from reduction in MNCV,
NBF and decrease in tail flick latency. We observed 14% and
64% deficit in MNCV and NBF respectively after 8weeks of
diabetes induction. These results are consistent with the
previous reports, wherein similar reductions of MNCV and
NBF in STZ-induced diabetic rats were reported (Cameron and
Cotter, 2002; Cotter et al., 2002).
Generation of ROS and reduced generation and/or bioactiv-
ity of nitric oxide by the endothelial nitric oxide synthase in
diabetic condition are well established. It has been demonstrated
that oxidative stress produce nerve conduction velocity deficits
in diabetic rats (Cameron and Cotter, 1995; Cameron et al.,
1994; Cameron et al.1998; Cotter et al., 1995; Karasu et al.,
1995; Love, et al., 1996). Reduction in nerve conductionvelocity in our study was prevented up to 78% at U83836E
(3mg/kg) and complete reversal was observed with U83836E
(9mg/kg).
A number of reports indicate that peripheral diabetic
neuropathy (PDN) is a hypoxic neuropathy. Decrease in
NBF and resulting endoneurial hypoxia may cause MNCV
slowing (Cameron and Cotter, 1997; Coppey et al., 2001a,
b; Obrosova et al., 2002). Impaired endothelium depen-
dent vasodilatation has been demonstrated in various
vascular beds of animal models of diabetes and humans
with type 1 and type 2 diabetes (De Vriese et al., 2000;
Pieper and Siebeneich, 1997). Free radicals such as O2
−
and OH− cause vascular endothelial damage and reduced
NO− mediated vasodilatation (Cameron and Cotter, 1997).
Studies have provided evidence that O2
− and peroxynitrite
impairs endothelium dependent vascular relaxation of
epineural arterioles of the sciatic nerve from diabetic
rats (Coppey et al., 2002; Nishikawa et al., 2000). We
observed 64% decrease in sciatic NBF in diabetic rats.
This deficit in composite NBF was improved significantly
but not completely reversed upon U83836E treatment. It
has been reported that complete normalization of NBF is
not required for correction of MNCV in diabetic rats
(Obrosova, 2003).
Several groups have suggested that vascular mechanism
play an important role in MNCV deficits in PDN (Cameron et
al., 2001; Coppey et al., 2001a,b; Low et al., 1997). In addition
to vascular mechanisms, nonvascular mechanisms have also
been reported to cause conduction deficits (Li et al., 2004;
Obrosova, 2003). Enhancement of neurotrophic factors by
prosaposin-derived peptide has shown to preserve nerve
conduction, but not NBF by reversible modification of the
metabolic and neurotrophic state of the neuron and Schwann
cells in the peripheral nervous system (Mizisin et al., 2001).
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due to oxidative stress restore normal nerve energy state and
prevent reduction in conduction deficits (Obrosova et al.,
2004). PJ34, a PARP inhibitor normalized nerve energy level
to state that completely reversed diabetes induced MNCV
deficits (Obrosova, 2003).
U83836E might increase energy metabolism, reduce
AGE formation and inflammation as reported with other
antioxidants (α-lipoic acid, vitamin E, vitamin C and N-
acetyl-L-cysteine). α-Lipoic acid has shown to increase
energy metabolism and myo-inositol level in diabetic
nerves (Kishi et al., 1999; van Dam, 2002). Vitamin C
and vitamin E have been reported to decrease formation
of AGE products (Singh et al., 2001). N-Acetyl-L-cysteine
and α-tocopherol have shown to reduce pro-inflammatory
cytokines (IL, TNF-α), chemokines and C-reactive proteins
in diabetic rats (Jialal et al., 2002; Sagara et al., 1996).
U83836E treatments have shown reduction of apoptotic
cell death, which is usually a consequence of oxidative
stress (Patel and Gores, 1997).
In diabetic rats, we observed a significant increase in MDA
levels and reduction in antioxidant enzyme activity. U83836E
treatment significantly reduced MDA levels and increased
antioxidant enzyme (SOD and catalase) activity in diabetic rats.
U83836E have already been reported to increase SOD levels
and decrease MDA levels in streptozotocin low dose-treated
mice (Papaccio et al., 1995). α-Lipoic acid, an antioxidant, has
also been reported to improve levels of these antioxidant
enzymes and restore deficits in diabetic neuropathy (Stevens et
al., 2000). Vitamin C and E normalize antioxidant enzyme
expression in diabetic rats (Sindhu et al., 2004). Melatonin, a
potent antioxidant, has shown to produce an increase in
antioxidant enzyme expression (Esparza et al., 2005). There
might be possibility that U83836E enhance antioxidant enzyme
expression, thereby increasing antioxidant enzyme levels and
decrease the formation of free radicals leading to inhibition of
lipid peroxidation.
Neuropathic pain is commonly associated with diabetic
neuropathy. We observed reduction in tail flick latencies in hot
and cold immersion test in diabetic rats, which indicate thermal
hyperalgesia. Several researchers have reported similar hyper-
algesia in diabetic rats (Anjaneyulu and Chopra, 2004; Ciruela
et al., 2003; Wuarin-Bierman et al., 1987). Mechanisms, such as
tissue injury due to ischemia, sensitization of peripheral
receptors and ectopic activity in sprouting fibers and alterations
in dorsal root ganglia cells, are reported to contribute to change
in nociception (Jensen and Baron, 2003). In the present study,
we observed a significant improvement in tail flick response
latency for hot as well as cold immersion performance upon
U83836E treatment, thus suggesting the role of oxidative stress
in nociceptive changes in diabetic rats.
In conclusion, U83836E showed significant protection in
diabetic neuropathy as evident from improvement in MNCV,
NBF, antioxidant enzyme levels, reduction in thermal hyper-
algesia and lipid peroxidation in treated diabetic rats. This study
suggests the role of oxidative stress in diabetic neuropathy and
beneficial effects of U83836E in diabetic neuropathy.Acknowledgements
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